<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859179</url>
  </required_header>
  <id_info>
    <org_study_id>COA. MURA2020/1420</org_study_id>
    <nct_id>NCT04859179</nct_id>
  </id_info>
  <brief_title>Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women</brief_title>
  <official_title>Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College&#xD;
      of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However,&#xD;
      in Thailand, there are no standard protocol for SMA prenatal carrier screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive&#xD;
      disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of&#xD;
      symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months&#xD;
      old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately&#xD;
      1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as&#xD;
      high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and&#xD;
      American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and&#xD;
      prenatal carrier screening in general population. In Thailand, there are no standard protocol&#xD;
      for SMA prenatal carrier screening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Rate of acceptance of prenatal carrier screening for spinal muscular atrophy</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of acceptance of prenatal carrier screening for spinal muscular atrophy among pregnant women seeking prenatal care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy</measure>
    <time_frame>12 months</time_frame>
    <description>Factors associated rate of acceptance of prenatal carrier screening for spinal muscular among pregnant women seeking prenatal care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copies number of SMN1 and SMN2 genes in pregnant women</measure>
    <time_frame>12 months</time_frame>
    <description>Copies number of SMN1 and SMN2 genes in pregnant women among individuals who accepted carrier screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carrier frequency among individuals who accepted carrier screening</measure>
    <time_frame>12 months</time_frame>
    <description>Screen positive rate or rate of having 1 copy of SMN1 among individuals who accepted carrier screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnant women's attitudes toward spinal muscular atrophy and carrier screening</measure>
    <time_frame>12 months</time_frame>
    <description>After genetic counseling, pregnant women's attitudes toward spinal muscular atrophy and carrier screening will be evaluated by validated questionnaire.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, plasma and DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women who came to antenatal care clinic at Ramathibodi Hospital, Mahidol&#xD;
        University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal age &gt; 18 years&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age â‰¤ 14 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to participate the research trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chayada Tangshewinsirikul</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chayada Tangshewinsirikul</last_name>
    <phone>0898905444</phone>
    <email>chayada.tan@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takol Chareonsirisuthigul</last_name>
    <phone>021677066</phone>
    <email>takol.cha@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Chayada Tangshewinsirikul</investigator_full_name>
    <investigator_title>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University</investigator_title>
  </responsible_party>
  <keyword>spinal muscular atrophy</keyword>
  <keyword>prenatal screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

